Drug Trial Radar · NCT03961009
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Apr 30, 2019
Primary completion
Dec 21, 2020
Study completion Dec 21, 2020
Sponsor
- Lead sponsor
- Kedrion S.p.A.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
Conditions
- Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%Biological
Kedrion intravenous immunoglobulin (IVIg) 10%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate of Acute Serious Bacterial Infections (ABSIs)Time frame: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Allergy Associates of the Palm Beaches
North Palm Beach, Florida
Rush University Medical Center
Chicago, Illinois
Dr. Henry J. Kanarek - Allergy, Asthma & Immunology
Overland Park, Kansas
Midwest Immunology Clinic and Infusion Center
Plymouth, Minnesota
Allergy and Immunology Associates
Little Silver, New Jersey
University of Buffalo
Buffalo, New York
Optimed Research
Columbus, Ohio
Ohio Clinical Research Associates, Inc.
Mayfield Heights, Ohio
Toledo Institute of Clinical Research Inc
Toledo, Ohio
Allergy Partners of North Texas Research
Dallas, Texas
AARA Research Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.